A combination of the cholinesterase inhibitor donepezil and the N-methyl D-aspartate (NMDA) receptor antagonist memantine improves the clinical שstatus of Alzheimer patients and slows disease progression, investigators reported in San Juan, Puerto Rico.
In a multicenter study, Dr. Pierre Tariot of the University of Rochester and colleagues randomized 403 patients with moderate to severe Alzheimer disease to receive either memantine 10 mg twice daily or placebo, in addition to donepezil. To be eligible for the study, patients were required to be on a stable daily dose of donepezil for at least three months.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!